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ABSTRACT
Objective: Value of information (VOI) analysis informs
decision-makers about the expected value of conducting
more research to support a decision. This expected value of
(partial) perfect information (EV(P)PI) can be estimated by
simultaneously eliminating uncertainty on all (or some)
parameters involved in model-based decision-making. This
study aimed to calculate the EVPPI, before and after collect-
ing additional information on the parameter of a probabilis-
tic Markov model with the highest EVPPI.
Methods: The model assessed the 5-year costs per quality-
adjusted life year (QALY) of three bronchodilators in chronic
obstructive pulmonary disease (COPD). It had identiﬁed
tiotropiumas the bronchodilatorwith the highest expected net
beneﬁt. Total EVPI was estimated plus the EVPPIs for four
groups of parameters: 1) transition probabilities between
COPD severity stages; 2) exacerbation probabilities; 3) utility
weights; and 4) costs. Partial EVPI analyses were performed
using one-level and two-level sampling algorithms.
Results: Before additional research, the total EVPI was
€1985 per patient at a threshold value of €20,000 per QALY.
EVPPIs were €1081 for utilities, €724 for transition prob-
abilities, and relatively small for exacerbation probabilities
and costs. A large study was performed to obtain more
precise EQ-5D utilities by COPD severity stages. After using
posterior utilities, the EVPPI for utilities decreased to almost
zero. The total EVPI for the updated model was reduced to
€1037. With an EVPPI of €856, transition probabilities were
now the single most important parameter contributing to the
EVPI.
Conclusions: This VOI analysis clearly identiﬁed parameters
for which additional research is most worthwhile. After
conducting additional research on the most important
parameter, i.e., the utilities, total EVPI was substantially
reduced.
Keywords: COPD, cost-utility, Markov model, value of
information.
Introduction
Decision-analytic models are commonly used to
analyze the costs and cost-effectiveness of pharmaceu-
ticals. Originally, these models were mostly determin-
istic and only considered uncertainty around model
parameters in sensitivity analyses. In later years, these
models developed into probabilistic models in which
uncertainty around input parameters was considered
simultaneously by entering prespeciﬁed distributions
for these parameters [1,2]. These probabilistic models
allowed displaying the resulting uncertainty around
costs and effects on cost-effectiveness planes and
by means of cost-effectiveness acceptability curves
(CEACs) [3] and frontiers [4]. Recently, value of infor-
mation (VOI) analysis has received increasing atten-
tion in the area of economic evaluations in health care
[5–9] and can be seen as a valuable extension of proba-
bilistic cost-effectiveness analysis, because, unlike
CEACs, it provides information on the consequences
of adopting the wrong treatment strategy.
In probabilistic cost-effectiveness models, the treat-
ment strategy to adopt is identiﬁed as the strategy with
the highest expected net beneﬁt. Net monetary beneﬁt
is calculated as the total number of health effects, in
this case quality-adjusted life years (QALYs), multi-
plied by the willingness to pay (WTP) for a QALY
minus the total costs: (QALY ¥ WTP) - C [10,11].
Expected net beneﬁt is deﬁned as the mean of the net
beneﬁts across all model iterations. VOI analysis is a
Bayesian decision analytic approach which acknowl-
edges that the decision to adopt and reimburse the
strategy with the highest expected net beneﬁt is based
on currently available information that is surrounded
by uncertainty. As long as there is uncertainty, there
will always be a chance the wrong decision is made.
Making the wrong decision comes with a cost that is
equal to the beneﬁts forgone because of the wrong
decision. The expected costs of uncertainty can be
determined by: 1) the probability that a decision based
on mean net beneﬁt is wrong; and 2) the size of the
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opportunity loss if the wrong decision is made. A VOI
analysis informs decision-makers about the expected
costs of uncertainty and, hence, the value of collecting
additional information to eliminate or reduce uncer-
tainty [9]. The total expected value of perfect informa-
tion (EVPI) estimates the value of simultaneously
eliminating all uncertainty on all parameters involved
in taking a decision [7]. A VOI analysis may also
provide information on the parameters for which addi-
tional research is most useful. Estimates of partial
EVPI (EVPPI) can identify the parameters which uncer-
tainties contribute most to the overall decision
uncertainty. This information is valuable because a
decision-maker does not only have to decide which
treatment strategy to adopt but also whether more
research regarding the decision is desirable. Since
2004, the National Institute for Clinical Excellence
“Guide to the Methods of Technology Appraisal”
states that candidate topics for future research may be
best prioritized by considering the value of additional
information in reducing the degree of decision uncer-
tainty [12].
Value of information has been developed and
successfully applied outside the health-care sector
[13–16]. Health Technology Assessment (HTA)-
researchers have adopted and further developed the
concept for application in health-care decision-making
[5,17]. Several authors have presented methods to cal-
culate partial EVPI in probabilistic decision analytic
models [8,17,18]. There has been some confusion
because these different computational approaches all
differ slightly. Hence, we have recently seen the publi-
cation of a few articles further clarifying the method-
ology [19,20]. Although the number of case studies is
increasing [9,21–24], the number of actual applica-
tions of VOI in health care is still limited.
This article describes a VOI analysis based on a
previously published probabilistic Markov model to
assess the cost-effectiveness of bronchodilator therapy
in chronic obstructive pulmonary disease (COPD)
[25,26]. The objective of this article is to determine the
impact that actually collecting additional data on one
key parameter of the model, namely utilities, has on
the overall model uncertainty. Hence, our study is an
application of the VOI methodology to the realistic
problem of choosing between bronchodilators in
COPD. In the methods section, we ﬁrst present the
model, the prior utility data, and the posterior utility
data that were obtained after a Bayesian update of the
prior data with the newly collected data. Then, we
present the VOI methodology and the sampling algo-
rithms that we have used to calculate the EVPI and
partial EVPI. We introduce a notation that can be
easily understood by researchers without a mathemati-
cal background. In the Results section, we present the
value of collecting additional information before and
after collecting new utility data.
Methods
The COPD Markov Model
Structure of the Markov model. The VOI analysis was
applied to a probabilistic Markov model comparing
the 5-year costs and effects of treating patients with
moderate to very severe COPD with either one of three
bronchodilators: tiotropium, salmeterol or ipratro-
pium. Details of the model have been published previ-
ously [25,26], but in brief, COPD patients were
classiﬁed into three disease states of increasing severity
based on prebronchodilator forced expiratory volume
(FEV) in 1 second as a percentage of the predicted
value (FEV1 % pred.) according to the Global Initiative
for Chronic Obstructive Lung Disease (GOLD) guide-
lines [27]: moderate COPD (50%  FEV1 % pred.
< 80%), severe COPD (30%  FEV1 % pred. < 50%),
and very severe COPD (FEV1 % pred. < 30%).
In prespeciﬁed time intervals of 1 month (i.e.,
Markov cycles), patients could remain in the same
disease state, transition between disease states or die.
During each cycle, patients also had a certain risk to
experience an exacerbation, which was either severe or
nonsevere, the risk to experience an exacerbation
varied by disease state and treatment group. Given
disease state, exacerbation probabilities were assumed
to be constant over time. Resource use and costs were
assigned to disease states and exacerbations. Primary
outcome of the model was the cost per QALY over a
time period of 5 years.
Model input parameters. Probabilistic input param-
eters of the model included transition probabilities
between disease states, the risk to experience an exac-
erbation, utilities associated with disease states and
exacerbations, and costs (resource use) of maintenance
therapy and exacerbations. Uncertainty around these
parameters was considered simultaneously and the
parameters were entered into the model as prespeci-
ﬁed, independent distributions. We adopted a Dirichlet
distribution for transitions between disease states [28],
beta distributions for exacerbations and utilities and
a gamma distribution for the estimation of resource
use [29]. Second-order Monte-Carlo simulations were
undertaken in which values were randomly drawn
from these distributions. Fixed model parameters
included discount rates for costs and effects and the
baseline distribution of patients over COPD severity
states. Details on the prior and posterior beta distribu-
tion of utilities are given in the next section.
All input parameters reﬂect the Dutch situation. The
model starts with 73% of the patients in moderate
COPD, 21% in severe COPD, and 6% in very severe
COPD [30,31]. Probabilities to transition between
disease states and to have exacerbations were based on
clinical trial data [32–34]. The mortality risk in each
disease state was estimated by combining the age- and
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sex-speciﬁc all cause mortality rates among COPD
patients [35] with a relative mortality risk of 1.2 per 10
units decline in FEV1 % pred. [30]. Resource use and
costs (price level 2001) were published previously [25].
Utility values per disease state for the base-case analysis
were based on empirical data from an observational
study in patients with COPD classiﬁed into the GOLD
stages [36]. During cycles in which patients experienced
an exacerbation, it was assumed that the utility value
was reduced by 15% in case of a nonsevere exacerba-
tion [37] and by 50% in case of a severe exacerbation
[38]. In accordance with the latest Dutch guidelines for
pharmacoeconomic research [39], the discount ratewas
set to 4% for costs and 1.5% for utilities.
Prior and posterior utility data. Before additional data
collection, the parameter with the highest EVPPI was
the utility value for each of the different COPD severity
states (see results). This model parameter contributed
most to the overall uncertainty as to which bronchodi-
lator treatment to adopt given the currently available
information. In this initial analysis, we used mean (SE)
EQ-5D index scores for moderate, severe, and very
severe COPD of 0.755 (0.031), 0.748 (0.060), and
0.549 (0.104), respectively [36]. These were obtained
as part of the Swedish Obstructive Lung Disease in
Northern Sweden study among a sample of 179 COPD
patients [40]. Then, additional utility research was
performed in a sample of 1235 patients from a large
ongoing trial in patients with moderate to very severe
COPD, who completed the EQ-5D questionnaire at
baseline [41]. As in the Swedish study, the EQ-5D
scores were valued using the “MVH A1 value set,”
which was developed in the UK at the Measurement
and Valuation of Health study [42]. The mean (SD, SE)
EQ-5D index scores for moderate (n = 622), severe
(n = 513), and very severe COPD (n = 91) in this study
were 0.787 (SD: 0.195, SE: 0.008), 0.750 (SD: 0.211;
SE: 0.009), and 0.647 (SD: 0.230, SE: 0.024) for mod-
erate, severe, and very severe COPD, respectively. On
average, the standard errors of these latter values were
about one-quarter of the initial values. The newly col-
lected information on utilities was combined with the
prior information on utilities using formal Bayesian
updating to obtain the posterior utilities. Table 1
shows the prior and posterior parameters of the beta
distribution that was assigned to the utilities. The pos-
terior beta distribution has parameters a2, calculated
as a0 + a1, and b2, calculated as b0 + b1 (Table 1).
VOI Analysis
EVPI. The overall EVPI is equal to the net beneﬁt of the
optimal strategy given perfect information minus the
net beneﬁt of the strategy that would be adopted given
current information, averaged over all model iterations.
In other words, the EVPI is equal to the average of the
maximum net beneﬁts across all model iterations (i.e.,
the expected net beneﬁt using perfect information),
minus the maximum of the average expected net
beneﬁts across all treatment strategies (i.e., the expected
net beneﬁt using the currently available [imper-
fect] information) [8]. Formally, this denoted as
EVPI E
d
NB d
d
E NB d= ( )[ ]{ } − ( )[ ]{ }q q qmax , max ,q
where NB(d, q) is the net beneﬁt function for decision d
and parameters q, and Eq denotes an expectation over
the full joint distribution of q. In this case, the expected
value of a parameter is obtained by taking the mean
value of that parameter over N simulations. For ease of
comprehension, we will use the following notation:
the EVPI will be denoted as Meanq[MaxT(NB)] -
MaxT[Meanq(NB)]. The overall EVPI analysis was per-
formed using a one-level sampling algorithm (see
Table 2).
EVPPI. In the current model, there were four groups
of parameters contributing to the overall uncertainty
in the model: 1) transition probabilities; 2) probabili-
ties of experiencing an exacerbation; 3) utilities; and 4)
costs. Each group contains individual model param-
eters that were related and often obtained from the
same sources but vary by COPD severity and exacer-
bation severity. The parameters were grouped because,
for additional research to be efﬁcient, it will probably
be designed to generate information on multiple
Table 1 Prior and posterior parameters of the beta distribution of utility values
Prior utilities New utilities Posterior utilities
a0 b0 a1 b1 a2 b2
Moderate COPD without exacerbations 144.57 46.91 2060.55 557.68 2205.12 604.60
Moderate COPD with nonsevere exacerbations 99.45 55.52 237.72 117.64 337.17 173.16
Moderate COPD with severe exacerbations 12.94 21.34 14.61 22.52 27.55 43.86
Severe COPD without exacerbations 38.42 12.94 1625.16 541.72 1663.58 554.66
Severe COPD with nonsevere exacerbations 35.24 20.19 247.91 140.97 283.15 161.15
Severe COPD with severe exacerbations 9.15 15.31 15.01 25.02 24.16 40.34
Very severe COPD without exacerbations 12.02 9.87 253.77 138.46 265.79 148.33
Very severe COPD with nonsevere exacerbations 10.01 11.44 141.60 115.88 151.61 127.32
Very severe COPD with severe exacerbations 3.68 9.72 14.53 30.38 18.21 40.10
COPD, chronic obstructive pulmonary disease.
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individual parameters within a group. We calculated
the EVPPI (partial EVPI) for these four subsets of
parameters, i.e., the parameters of interest. This partial
EVPI analysis was performed to get insight into the
value of obtaining perfect information on these param-
eters to guide future research toward those parameters
with the highest expected VOI [5].
A partial EVPI was performed using a two-level
sampling algorithm in which multiple simulations
were performed for different values of the parameter of
interest [7]. The two-level sampling algorithm uses two
nested levels of Monte Carlo sampling over the plau-
sible ranges for both the parameter(s) of interest (qi),
and the remaining uncertain parameters (qc). Before
running the two-level sampling algorithm, an EVPI
analysis was performed as described earlier and the
value of the treatment with the highest mean net
beneﬁt (MaxT[Meanq(NB)]) is recorded. Also, the
mean of the maximum expected net beneﬁts across all
model iterations (Meanq[MaxT(NB)]) is recorded. The
two-level sampling algorithm that we have applied is
outlined in Box 1. After completion of all steps in Box
1, all data that are needed to calculate the partial EVPI
for the parameter of interest are available. The partial
EVPI for the parameter of interest can be calculated
by either one of three methods: 1) subtracting the
difference between the Meanqi[Meanqc{MaxT(NB|qi)}]
and the Meanqi[MaxT{Meanqc(NB|qi)}] from the overall
EVPI [18]; 2) subtracting the MaxT[Meanq(NB)] from
the Meanqi[MaxT{Meanqc(NB|qi)}] [20]; or 3) sub-
tracting the MaxT[Meanqi{Meanqc(NB|qi)}] from the
Meanqi[MaxT{Meanqc(NB|qi)}] [43]. Mathematically,
these calculations are equivalent when the numbers of
iterations in the model simulations are large enough. In
this article, we have used the ﬁrst method [18].
Figure 1 shows the two-level analyses and the three
methods to determine the partial EVPI.
Although the number of iterations that is sufﬁcient
to estimate partial EVPI can be estimated [8], com-
puter time can be an insuperable problem to straight-
forward two-level partial EVPI analysis [8]. To work
around the computer-time problems associated with
two-level sampling, a one-level algorithm has been
proposed as a shortcut to partial EVPI analysis
[8,17,18]. This shortcut algorithm is almost the same
as the algorithm for the calculation of the EVPI that is
outlined in Table 2. Nevertheless, instead of sampling
from all parameters simultaneously, the one-level
partial EVPI algorithm involves sampling from the
parameter of interest, while keeping all other param-
eters constant at their mean value [19,20]. The partial
EVPI is then calculated as 1) the difference between the
Meanq[MaxT(NB|1)] and the MaxT[Meanq(NB|1)] [18]
where the underscore |1 denotes the situation that
the parameters not of interest (qc) are ﬁxed at their
mean value; or 2) as the difference between the
Meanq[MaxT(NB|1)] and the MaxT[Meanq(NB)] [20].
Again, these calculations are equivalent for sufﬁciently
large numbers of iterations and we have used the ﬁrst
method [18]. The validity of the one-level algorithm is,
among other factors, conditionally upon the linearity
of the model and upon the absence of correlation
between (the subset of) the parameter of interest and
the other variables in the model.
Analysis. The analysis was performed from a health-
care perspective. The number of iterations for the EVPI
analysis and the one-level EVPPI analysis was set to
10,000. For the two-level algorithms, the number of
inner loops was set to 1000, whereas the number of
outer loops was set to 500. The number of outer loops
was smaller than the number of inner loops because, in
this speciﬁc analysis, there is less variation in the outer
loop than in the inner loop. In the outer loop, we
sample from the utility parameter(s) (qi) only and hold
these parameters constant at their sampled values. In
the inner loop, we sample from all other model param-
eters not of interest (qc) and run the model for each set
of parameters that is drawn. In addition, studies by
Brennan et al. suggest that fewer samples on the outer
Table 2 Method of calculating the overall EVPI
Model iterations
Net beneﬁt (NB)
Maximum NB across iterations
NB gained when having
perfect informationTiotropium Salmeterol Ipratropium
1 58,630 58,516 57,333 58,630 58,630 - 58,630 = 0
2 57,525 55,867 61,130 61,130 61,130 - 57,525 = 3605
3 59,527 59,854 58,293 59,854 59,854 - 59,527 = 327
4 60,428 57,787 55,754 60,428 60,428 - 60,428 = 0
5 . . . . . . . . . . . . . . .
n = 10,000 NBtio NBsal NBipra MaxT(NB) MaxT(NB) -NBtio
EVPI =
Mean 59,419* 57,488 56,602 60,457† (0 + 3605 + 327 + 0 + etc)/10,000 = 1037‡
60,457 - 59,419 = 1037‡
MaxT[Meanq(NB)] Meanq[MaxT(NB)] Meanq[MaxT(NB)] -MaxT[Meanq(NB)]
*Tiotropium has the highest expected NB, MaxT[Mean(NB)], and is the optimal strategy with currently available information.
†This is the mean of the maximum expected NBs across all model iterations, Mean[MaxT(NB)], i.e., the expected NB with perfect information.
‡EVPI is calculated as the average gain in NB across the model iterations, and is equal to Mean[MaxT(NB)] (60,457) minus MaxT[Mean(NB)] (59,419).
EVPI, expected value of perfect information.
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level and larger numbers of samples at the inner level
might be the most efﬁcient approach when trying to
minimize bias and random error [20]. In his case
studies, stable results were obtained with 500 inner
loops and 100 outer loops. Because of the complexity
of our model, we have chosen a larger number of inner
and outer loops, but the numbers were chosen such
that one analysis could be performed within 12 hours
(i.e., could be run during the night). All analyses were
performed in Excel in Microsoft Ofﬁce 10.
The overall EVPI and partial EVPIs were calculated
before and after the model was ﬁlled with posterior
utility data. The EVPI was plotted as a function of the
threshold value of the maximum WTP for a QALY
(i.e., ceiling ratio). The partial EVPI analysis was per-
formed for the four subgroups of input parameters:
transition probabilities, exacerbation probabilities,
utilities and costs of maintenance therapy and exacer-
bations. In the partial EVPI analysis, a threshold value
of €20,000 for a QALY was used. This value was
chosen because it is frequently mentioned in debates
about the cost-effectiveness of health-care interven-
tions in The Netherlands. The value originates from
two Dutch medical practice guidelines, where it has
been used as a reference point [44,45] and it has fre-
quently been used thereafter [46].
Results
Cost-Effectiveness
Table 3 shows the cost-effectiveness outcomes before
and after the utility study was conducted. The table
shows that in both analyses, tiotropium was associ-
ated with improved health outcomes and lower
overall costs compared with salmeterol and ipratro-
pium. Mean costs per patient for tiotropium were
€239 (SE €977) lower than for salmeterol, which in
turn were €751 (SE €1501) lower than for ipratro-
pium. Differences between treatments in the number
of QALYs were small. In both analyses, the number
of QALYs was about 0.15 higher for tiotropium than
for salmeterol and ipratropium, which both gener-
ated a similar number of QALYs. The standard errors
for QALYs ranged from 0.17 to 0.28 in the initial
analysis and from 0.10 to 0.22 in the analysis based
on the newly collected utilities. At a threshold value
of €20,000 for a QALY, the expected net monetary
beneﬁts before the utility study were €56,820 for
tiotropium, €54,380 for salmeterol, and €53,629
for ipratropium. After collecting additional utility
data, these values increased to €59,419 for tiotro-
pium, €57,488 for salmeterol, and €56,602 for
ipratropium.
Box 1
Two-level sampling algorithm for the calculation of partial EVPI
Start outer loop
Step 1: Sample once from the parameter(s) of interest (qi) and hold that parameter constant at its sampled
value.
Start inner loop
Step 2: Sample once from all model parameters not of interest (qc) and run the model once (i.e., one model
iteration).
Step 3: Record the net beneﬁt of each treatment strategy given perfect information on qi: NB|qi.
Step 4: Determine the treatment with the highest net beneﬁt given perfect information on qi and record this
value: MaxT(NB|qi).
Step 5: Repeat steps 2, 3 and 4 a large number of times (in this study 1000 times).
End of inner loop
Step 6: Record the mean net beneﬁt of each strategy Meanqc(NB|qi).
Step 7: Record the mean of the MaxT(NB|qi): Meanqc{MaxT(NB|qi)}.
Step 8: Determine the treatment with the highest mean net beneﬁt and record this value:
MaxT{Meanqc(NB|qi)}.
Step 9: Repeat steps 1 to 8 a large number of times (in this study 500 times)
End of outer loop.
Step 10: Calculate the mean of the values recorded in steps 6 to 8. These are the Meanqi{Meanqc(NB|qi)}, the
Meanqi[Meanqc{MaxT(NB|qi)}], and the Meanqi[MaxT{Meanqc(NB|qi)}].
Step 11: Calculate the partial EVPI by 1) subtracting the difference between the Meanqi[Meanqc{MaxT(NB|qi)}]
and the Meanqi[MaxT{Meanqc(NB|qi)}] from the EVPI; 2) subtracting the MaxT[Meanq(NB)] from
the Meanqi[MaxT{Meanqc(NB|qi)}]; or 3) subtracting the MaxT[Meanqi{Meanqc(NB|qi)}] from the
Meanqi[MaxT{Meanqc(NB|qi)}].
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Based on mean values, tiotropium dominated both
salmeterol and ipratropium, because it was both more
effective and less costly. The CEACs of the two analy-
ses are presented in Fig. 2. The curves are quite similar.
If decision-makers are not willing to pay anything for
an additional QALY, the probability that tiotropium
was optimal was around 48% in both analyses com-
pared with 36% for salmeterol and 17% for ipratro-
pium. For tiotropium, this increased to 59% at a
ceiling ratio of €3000 in the prior analysis and 61% at
a ceiling ratio of €3400 in the posterior analysis. The
greater precision on utilities slightly increased the
probability that tiotropium had the highest net beneﬁt
and reduced the probability that ipratropium had the
highest net beneﬁt. At a ceiling ratio of €5000, the
probability that tiotropium had the highest net beneﬁt
increased from 58% in the prior analysis to 61% in the
posterior analyses, whereas the probability that iprat-
ropium was most cost-effective decreased from 15% to
12%. At a ceiling ratio of €10,000, the probability that
tiotropium had the highest expected net beneﬁt
increased from 54% in the prior analysis to 59% in the
posterior analyses. For ipratropium, it reduced from
20% to 16%.
EVPI
Figure 3 presents the overall EVPIs before the utility
study and after the utility study as a function of the
ceiling ratio. Before the utility study, the EVPI started
at a value of €377 per patient and reduced to a
minimum of €284 per patient at a value of the ceiling
ratio of approximately €1800 per QALY. From this
point onwards, the EVPI increased steadily reaching a
value of €1985 per patient at a ceiling ratio of €20,000
and a value of €4301 per patient at a ceiling ratio of
€40,000 per QALY. After the results from the utility
study had been incorporated into the model, the EVPI
started at €390, reduced to a minimum of €259 at a
value of the ceiling ration of approximately €3700 and
remained well below the ﬁrst curve. In the updated
model, the EVPI was about €1040 at a ceiling ratio of
€20,000 and €2386 at a ceiling ratio of €40,000.
Figure 1 Illustration of the two-level partial EVPI sampling algorithm given perfect information on qi. EVPI, expected value of perfect information; EVPPI,
expected value of partial perfect information.
Table 3 Mean (SE) 5-year costs and QALYs per patient before and after the additional utility study
Outcomes Tiotropium Salmeterol Ipratropium
Costs (in Euros) 7380 (504) 7620 (840) 8371 (1257)
QALYs: before the additional utility study 3.21 (0.17) 3.10 (0.23) 3.10 (0.28)
QALYs: after the additional utility study 3.34 (0.10) 3.26 (0.16) 3.25 (0.22)
QALY, quality-adjusted life year.
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In both curves, the EVPI initially fell as the value of
the ceiling ratio increased because the reduced prob-
ability of incurring an opportunity loss outweighed the
increased valuation of this opportunity loss. Because
the ceiling ratio increased from €0 to €2000, there was
a substantial increase in the probability that tiotro-
pium had the highest net monetary beneﬁt, i.e., an
increase from 48% to 60% in the prior analysis. This
increase outweighed the decrease in the value of the
opportunity loss and caused a reduction in EVPI. At
higher values of the ceiling ratio, the decrease in oppor-
tunity loss outweighed the small increase in probability
of incurring an opportunity loss.
Partial EVPI
The results of the partial EVPI analyses are presented
in Table 4. This table includes the results of the two-
level and the one-level algorithms before and after the
additional information on utilities was collected. Both
the one-level and two-level algorithms for calculating
partial EVPI before the additional data collection
showed that, among the different groups of param-
eters, utilities had the highest partial EVPI. Research
that would eliminate the uncertainty in this subset of
parameters would be worth €1081 per patient. The
second highest was the partial EVPI for transition
probabilities, which was €724 per patient. Doing addi-
tional research on exacerbation probabilities and costs
would not be of any value, because the partial EVPIs
for these parameters were very small. After the utility
study, the partial EVPI for utilities dropped to about
€0. In that analysis, only the partial EVPI for transition
probabilities was substantial, €856. Hence, doing
further additional research on transition probabilities
remained potentially worthwhile.
Population EVPI
So far, we have presented the (partial) EVPI per
patient. To determine a priori whether additional data
collection is beneﬁcial, the costs of data collection
should be compared to the population EVPI. The
population EVPI can be calculated by multiplying the
EVPI per patient with the number of patients eligible
for treatment. Using the Dutch COPD population
model by Hoogendoorn et al. [30], the number of
patients with physician-diagnosed moderate to very
severe COPD in The Netherlands has been estimated
to be 243,000. Even if we assume that only 20% of
these patients are facing the choice between bron-
chodilators, the population EVPI for The Netherlands
would already be €96 million. If the COPD popula-
tions of all Western countries were taken into account,
the population EVPI would have been enormous.
Hence, given the large potential target population for
COPD treatments, the value of additional information
will easily outweigh the costs of collecting this infor-
mation from a societal perspective.
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tional utility study for patients treated with
tiotropium, salmeterol or ipratropium. QALY,
quality-adjusted life year.
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Figure 3 EVPI before and after the additional utility study. Continuous
gray line: EVPI before collecting additional information on utilities; dashed
black line: EVPI after collecting additional information on utilities. EVPI,
expected value of perfect information.
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Discussion
The results of the VOI analysis before collecting addi-
tional data showed that the overall EVPI for the choice
between tiotropium, salmeterol, and ipratropium was
€1985 per patient at a ceiling ratio of €20,000. This is
the absolute limit of the value of further research that
would completely eliminate the uncertainty around the
parameters in the model. Partial EVPI analyses showed
that the costs of uncertainty were highest for the utility
values, followed by the transition probabilities
between COPD severity stages. Hence, collecting addi-
tional data on utilities was potentially of most value;
the expected value of eliminating uncertainty in this
subset of parameters was €1081. After having col-
lected additional information on utilities, the overall
EVPI was considerably reduced. In this posterior
analysis, the remaining overall EVPI was €1070 and
almost entirely because of uncertainty around disease
state transitions. The partial EVPI of the utilities was
reduced to almost zero. Collecting additional data on
exacerbation probabilities or resource utilization did
not appear to be of value.
That it would be most beneﬁcial to collect addi-
tional information on utilities and transitions between
disease states was something that we had not expected
beforehand, because we had found in our previous
studies that exacerbations and the costs of these
exacerbations were important drivers of the cost-
effectiveness of bronchodilator treatment [25,26].
Scenarios in which we had assumed a complete
absence of a difference between the treatments in
terms of exacerbation rates had a relatively great
impact on the cost-effectiveness ratios. Nevertheless,
such extreme uncertainties are unrealistic and not rep-
resented by the model. The model does include all the
uncertainty around exacerbation rates that was
observed in the clinical trials. Moreover, it is important
to note that, although sensitivity analyses have shown
that exacerbation rates inﬂuence the cost-effectiveness
rates of tiotropium compared to its alternatives, the
cost-effectiveness ratios remained below the decision
threshold of €20,000 per QALY. This difference in
observations from sensitivity analyses and EVPI analy-
ses clearly illustrates the beneﬁt of doing an EVPI
analysis. The value of collecting additional informa-
tion for a particular parameter depends not only on the
association with cost-effectiveness, but also on the
prior uncertainty about this parameter. Trying to inter-
pret the joint impact of the strength of the association
and the uncertainty without doing a formal VOI analy-
sis is difﬁcult and may easily lead to false conclusions
about the parameters for which additional data collec-
tion is most useful.
The crucial question after an EVPPI analysis on
currently available information is whether the ex-
pected value of additional information outweighs and
justiﬁes the cost of collecting additional information.
The actual costs of this utility study are hard to esti-
mate because the EQ-5D data were collected within
the context of a large clinical trial that was designed to
measure the decline in lung function over time [47].
Hence, the EQ-5D data could be collected at relatively
little additional costs. If we were to set up a new study
of the same size just for the purpose of collecting utility
values, the costs would probably have been higher.
Nevertheless, to get a sufﬁciently precise estimate of
utilities by GOLD stage would probably require far
fewer patients and thus, a much cheaper study. But in
some jurisdictions, cost-effectiveness models can only
be ﬁlled with country-speciﬁc data. Consequently, data
from patients in each separate country are needed. In
that case, a large multinational trial is a good oppor-
tunity to collect these data.
It is interesting to note, from the CEACs in Fig. 2,
that even though the EVPI was strongly reduced by the
use of new utility estimates with substantially lower
standard errors, the decision about which treatment to
adopt does not change. In both cases, tiotropium has
the highest probability of being optimal as well as the
highest expected net beneﬁt over the whole range of
threshold ICERs studied, and should therefore be
adopted. Nevertheless, before additional data collec-
tion, the partial EVPI of utilities was high and this
partial EVPI was our best estimate of the change in
expected net beneﬁt that we could get by doing addi-
tional research. It is important to stress that accept-
ability curves show just one element of the EVPI,
namely the probability that a decision based on the
mean net beneﬁt is correct. Thus, the probability of
Table 4 EVPI and Partial EVPI results for the base-case and alternative analysis
Before collecting additional information on utilities After collecting additional information on utilities
EVPI 1985 1037
Partial EVPI for parameter subset Two-level One-level Two-level One-level
Transition probabilities 724 694 856 860
Exacerbation probabilities 3 0 0 0
Utility weights 1081 813 0 1
Costs 7 0 0 0
The EVPPI is expressed in Euros.The value of the ceiling ratio was 20,000. Number of iterations for the one-level analysis: 10,000; number of iterations for the two-level analysis:
inner loop 1000, outer loop 500.
EVPI, expected value of perfect information; EVPPI, expected value of partial perfect information.
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making the wrong decision is the complement of the
curve. The curves do not show the second element of
the EVPI, which is the magnitude of the opportunity
loss or, in other words, the consequence of making the
wrong decision. It is precisely this magnitude of the
opportunity loss that is considerably reduced by doing
the additional utility study, which has considerably
reduced the SE of the QALY outcome. This limitation
of the acceptability curve is, for instance, discussed by
Groot Koerkamp et al. [48] In general, there is no one
on one relationship between the probability that an
alternative is the “true” preferred alternative and the
VOI. When the acceptability curve decreases, the EVPI
necessarily increases, but the reverse is not true [49].
Thus, the acceptability curve on its own might lead to
wrong conclusions by policymakers, as many people
would be inclined to think that at 95% certainty of
making the right decision, there is minimal value in
additional research, whereas at 65% certainty this
value from research would be high, whereas in truth
the opposite might be the case.
A word of caution is necessary about the uncer-
tainty incorporated in the model and about EVPI
analysis in general. An EVPI analysis only provides
information about the values of eliminating uncer-
tainty around the probabilistic parameters included in
the model. The characterization of the parameters and
the different types of uncertainty is a major challenge
and some forms of uncertainty may not have been
taken into account. For example, the new EQ-5D utili-
ties were obtained in a multinational trial and we are
uncertain how well these utilities represent the hetero-
geneity of the COPD population in The Netherlands.
Another example relates to the disease state transi-
tions. We incorporated all uncertainty around these
transitions as observed in clinical trials, but we are also
uncertain as to what extent these trials reﬂect real life.
To fully represent uncertainty and to establish a full
EVPI analysis would require a parameterization of
these types of uncertainty.
One could argue that the high EVPI for utilities is
partly due to the fact that we have deﬁned independent
beta distributions for moderate, severe, and very severe
COPD with and without exacerbations. Hence, it may
occur that the utility value that is drawn for severe
COPD is better than the value drawn for moderate
COPD. We have not built in an association between
the utilities by disease severity, in the sense that, when
a low utility is drawn for moderate COPD, a lower
value should be drawn for severe COPD. Such an
association would reduce the uncertainty and the
EVPI. Nevertheless, we doubt whether it reﬂects
reality, because it is well known that the association
between lung function and quality of life, though
present, is rather weak [50], even at a group level.
Therefore, we have chosen to let the uncertainty
around the utility data speak for itself and not build in,
a priory, a hierarchy for which the evidence is not
strong. At the number of model runs in the current
analyses, the average utility value for moderate COPD
is better than for severe COPD, which in turn is better
than for very severe COPD.
The results of the EVPPI analyses presented in
Table 4 clearly show that the sum of the partial EVPIs
does not add up to the total EVPI. This feature of partial
EVPI analysis has also been explored in other publica-
tions [19,20]. The EVPI indicates the value of perfect
information. Perfect information means that we have
perfect information about the parameter of interest qi,
and perfect information about the complementary
parameters, qc, at the same time. The partial EVPI for qi
is the value of perfect information about qi, given the
uncertainty about qc, whereas the partial EVPI for qc is
the value of perfect information about qc, given the
uncertainty about qi. Summing the partial EVPIs for qi
and qc does not return the EVPI. For this to happen, we
should sum the partial EVPI for qi and the value of
perfect information about qc, given perfect information
about qi. The difference between the EVPI and the sum
of the partial EVPIs complicates straightforward inter-
pretation of a VOI analysis. Obtaining perfect informa-
tion on one parameter of interest does not reduce the
EVPI to the same extent as may have been expected
(falsely) from the value of the partial EVPI for that
parameter. Hence, the importance of a parameter for
further research should not be judged by the reduction
in EVPI [19]. The added value of a partial EVPI analysis
is to set priorities with regard to the parameters for
which additional data collection is most beneﬁcial by
ranking them according to their expected value of
research that would eliminate the uncertainty.
In this study, we compared the outcomes of a partial
EVPI analysis obtained with a two-level analysis with
a one-level analysis. Theoretically, the two-level analy-
sis provides the correct values of the EVPPI. The
required numbers of inner and outer loop iterations
are not known beforehand and, among other factors,
depend on the distribution and the number of uncer-
tain model parameters. In our analysis, the results of
the two-level analysis may have been biased because of
the limited number of iterations. Nevertheless, repeat-
ing some of the two-level analyses showed that the
consistency of outcomes across analyses was good. For
example, the EVPPIs of exacerbation probabilities and
costs were consistently around zero and the EVPPI of
utilities in ﬁve posterior analyses varied between €843
and €868. When a model is perfectly linear and no
correlation exists between input parameters, the one-
level sampling algorithms will provide estimates of the
EVPPI that are equal to the two-level sampling algo-
rithms. In this case, these assumptions are not fulﬁlled.
The Dirichlet distribution that was used for transition
probabilities, by deﬁnition, introduces correlation in
the transition rates. Moreover, an inherent character-
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istic of a Markov simulation is the multiplication of
matrices with transition probabilities over subsequent
cycles, causing the transitions to be nonlinear. Hence,
for that reason, the results of the one-level sampling
approach should be interpreted with care. Neverthe-
less, the results of the EVPPI analysis with the one-level
and the two-level sampling approach both indicated
that the EVPPI was highest for utilities and transition
probabilities although in absolute terms the EVPPIs of
especially the utilities differ.
In conclusion, this study has clearly shown the ben-
eﬁts of doing a VOI analysis. Before any additional
data collection, the VOI analysis at a ceiling ratio of
€20,000 estimated the EVPI to be €1985 per patient
and identiﬁed the utilities as the subset of parameters
with the highest EVPI. After additional research on
utilities was performed and a formal Bayesian update
of the utilities was conducted, the EVPPI of utilities
was reduced to almost zero. The EVPI was still €1070
and largely driven by the uncertainty in transition
probabilities, which would be the next best candidate
for doing additional research in the future. Such
research should focus on estimates of lung function
decline over time, because this decline drives the tran-
sition probabilities between COPD severity stages as
deﬁned by GOLD.
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